Get To Know Us

Brendan Doran, PharmD

Brendan Doran, PharmD

Chief Operating Officer

Brendan Doran, PharmD is a biotechnology executive with more than 15 years of experience leading teams in global drug development, clinical operations, and regulatory strategy. Prior to joining Clarametyx, Dr. Doran held senior leadership positions at CinRx Pharma and CTI Clinical Trials and Consulting Services. He has played key roles in strategic interactions with the U.S. Food and Drug Administration (FDA) and global regulatory bodies, guiding programs through critical stages of drug development. Dr. Doran previously practiced as a clinical pharmacist in a hospital setting and maintains an academic appointment at the University of Cincinnati James L. Winkle School of Pharmacy Division of Pharmaceutical Sciences. He earned a Bachelor of Science degree in Biology from Mercyhurst University and a Doctor of Pharmacy degree from the Lake Erie College of Osteopathic Medicine School of Pharmacy.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.